PREPARATION AND CHARACTERIZATION OF ETODOLAC BEARING EMULSOMES
Objective: Emulsomes are novel vesicular drug delivery system with an internal solid lipid core surrounded by one or more bilayers of phospholipids. Etodolac is a potent anti-inflammatory drug and is a drug of choice for the treatment of various diseases. The present study is focused on the development of emulsomes using etodolac as drug candidates having improved drug loading with sustained-release effect for patient compliance.
Methods: Emulsomes formulation composed of solid lipids (tristearin), phospholipids, cholesterol, stearylamine, and drug (etodolac) were prepared by lipid film hydration method followed by sonication to produce emulsomes of the nanometric size range. All the formulations were optimized by using box-behnken design of experiment considering 3 factors viz. drug to phospholipid ratio (A), tristearin to phospholipid ratio (B), stearylamine to phospholipid ratio (C) at 3 levels lower (-1), middle (0) and upper (+1). The response of the independent variables (A, B, C) was studied on the dependent variable viz. particle size (Y1), zeta potential (Y2), and entrapment efficiency (Y3). The responses were analyzed by design expert software to find out the optimized values of variables within the design space.
Results: Compatibility with excipients was established by FTIR studies. The developed emulsomes were spherical shape vesicles as analyzed by TEM. The optimized batch (OB) was evaluated for particle size, zeta potential, and entrapment efficiency with experimental values 383.1 ± 11.7 nm, 47.2 ± 1.3 mV and 80.1 ± 3.2% and predicted values 390.394 nm, 45.000 mV and 81.642 %, respectively. The experimental values were found in reasonable agreement with predicted values by the design of the experiment. In vitro drug release study showed sustained release of the drug (88.69 % after 24 h).
Conclusion: Etodolac loaded emulsomes is a novel drug delivery system and found to reliable in terms of various characteristic parameters like particle size, zeta potential, entrapment efficiency, and drug release. 3-factors 3-levels Box-behnken design of the experiment is a suitable design for the optimization of emulsomes.
2. Lala RR, Shinde AS, Nandvikar NY. Solid lipid nanoparticles: a promising approach for combinational drug therapy in cancer. Int J Appl Pharm 2018;10:17-22.
3. Lowell GH, Kaminski RW, Van Cott TC, Slike B, Kersey K, Zawoznik E, et al. Proteosomes, emulsomes, and cholera toxin B improve nasal immunogenicity of human immunodeficiency virus gp160 in mice: induction of serum, intestinal, vaginal, and lung IgA and IgG. J Infect Dis 1997;175:292–301.
4. Amselem AS, Yogev A, Zawoznik E, Friedman D. In emulsomes, a novel drug delivery technology. International Symposium on Control and Release of Bioactive Materials; 1994. p. 1369.
5. Amselem AS, Friedman D. Solid fat nanoemulsion, United States Patent no. 5,662,932(02-09-1997); 1997.
6. Kretschmar M, Amselem S, Zawoznik E, Mosbach K, Dietz A, Hof H, et al. Efficient treatment of murine systemic infection with Candida albicans using amphotericin B incorporated in nanosize range particles (emulsomes). Mycoses 2001;44:281–6.
7. Paliwal R, Paliwal SR, Mishra N, Mehta A, Vyas SP. Engineered chylomicron mimicking carrier emulsomes for lymph targeted oral delivery of methotrexate. Int J Pharm 2009;380:181-8.
8. Vyas SP, Subhedar R, Jain S. Development and characterization of emulsomes for sustained and targeted delivery of an antiviral agent to liver. J Pharm Pharmacol 2006;58:321-6.
9. Ucisik MH, Sleytr UB, Schuster B. Emulsomes meet S-layer proteins: an emerging targeted drug delivery system. Curr Pharm Biotechnol 2015;4:392–405.
10. Gupta S, Vyas SP. Development and characterization of Amphotericin B bearing emulsomes for passive and active macrophage targeting. J Drug Target 2007;15:206-17.
11. Ucisik MH, Kupcu S, Schuster B, Sleytr UV. Characterization of curcu emulsomes: nanoformulation for enhances solubility and delivery of curcumin. J Nanobiotechnol 2013;11:37.
12. Jones RA. Etodolac: an overview of a selective COX-2 inhibitor. Inflammopharmacology 1999;7:269–75.
13. Colebatch AN, Marks JL, Edwards CJ. Safety of non-steroidal anti-inflammatory drugs, including aspirin and paracetamol (acetaminophen) in people receiving methotrexate for inflammatory arthritis (rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, other spondyloarthritis). Cochrane Database Syst Rev 2011;11:CD008872.
14. James E, Reynolds F. Martindale: the extra pharmacopoeia. London: Royal Pharmaceutical Society; 1996.
15. Singh B, Dahiya M, Saharan V, Ahuja N. Optimizing drug delivery system using systemic “Design of experiments” part-2 fundamental aspects. Crit Rev Ther Drug 2005;2:215-93.
16. El-Malah Y, Nazzal S, Khanfar N. D-optimal mixture design: optimization of ternary matrix blends for controlled zero order drug release from oral dosage forms. Drug Dev Ind Pharm 2006;32:1207–18.
17. Singh B, Kumar R, Ahuja N. Optimizing drug delivery system using systemic “Design of experiments” part-1 fundamental aspects. Crit Rev Ther Drug 2004;22:27-105.
18. Moghddam SMM, Ahad A, Aquil M, Imam SS, Sultana Y. Optimization of nanostructured lipid carriers for topical delivery of nimesulide using box-behnken design approach. Artif Cells Nanomed Biotechnol 2017;45:617-24.
19. Rane S, Prabhakar B. Optimization of paclitaxel containing pH sensitive liposomes by 3-factor, 3-level box-behnken design. Indian J Pharm Sci 2013;75:420-6.
20. Rathee S, Kamboj A. Optimization and development antidiabetic phytosomes by box-behnken design. J Liposome Res 2017;28:1-26.
21. Kraisit P, Sarisuta N. Development of triamcinolone acetanide loaded nanostructured lipid carriers (NLCs) for buccal drug delivery using box-behnken design. Molecules 2018;23:982.
22. New RRC. Introduction and preparation of liposomes. In: New RRC. ed. Liposomes: A practical approach. Oxford: IRL Press; 1990. p. 1–104.
23. Govinder S, Pillay V, Chetty DJ. Optimization and characterization of bioadhesive controlled release tetracycline microspheres. Int J Pharm 2005;306:24-40.
24. Jores K, Mehnert W, Drechsler M, Bunjes H, Johann C, Mader K. Investigations on the structure of solid lipid nanoparticles by photon correlation spectroscopy, field flow fractionation and transmission electron microscopy. J Controlled Release 2004;95:217-27.
25. Pal A, Gupta S, Jaiswal A, Dube A, Vyas SP. Development and evaluation of tripalmitin emulsomes for treatment of experimental visceral leishmanisis. J Liposome Res 2012;22:62-71.
26. Singh N, Verma PK, Nanda S. Nanotechnology based oral formulations of tolbutamide by using biodegradable polymer. Int J Pharm Sci 2019;10:5599-605.
27. Shen J, Burgess DJ. In vitro dissolution testing strategies for nanoparticulate drug delivery systems: recent developments and challenges. Drug Delivery Transl Res 2013;3:409–15.
28. Yasir M, Sara UVS, Chauhan I, Gaur PK, Singh AP, Puri D. Solid lipid nanoparticles for nose to brain delivery of donepezil: formulation, optimization by box-behnken design, in vitro and in vivo evaluation. Artif Cells Nanomed Biotechnol 2018;46:1838-51.
29. Dholakia M, Dave R, Thakkar V, Rana H, Gohel M, Patel N. Newer ophthalmic in situ gel of moxifloxacin hydrochloride: optimization using box behnken stastical design. Int J Pharm Pharm Sci 2018;10:5-13.
30. Gopi G, Kannan K. Formulation development and optimization of nateglinide loaded ethyl cellulose nanoparticles by box-behnken design. Int J Pharm Pharm Sci 2015;7:310-5.
31. Ferreira SLC, Bruns RE, Ferreira HS, Matos GD, David JM, Brandao GC, et al. Box-Behnken design: an alternative for the optimization of analytical methods. Anal Chim Acta 2007;597:179–86.
This work is licensed under a Creative Commons Attribution 4.0 International License.